Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

Hematology Reports

Volumn 6, Issue 3, 2014, Pages 58-60

  Powers, Harry Ross ^a   Bachar, Moshe ^a   Savage, Natasha ^a,b   Toscano, Michael ^a   Dainer, Paul M ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute myeloblastic monocyt ic refractory; Azacitidine; Leukemia; Salvage chemotherapy

Indexed keywords

AZACITIDINE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; ANOREXIA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FILIPINO (PEOPLE); HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERURICEMIA; LEUKEMIA REMISSION; LEUKOCYTOSIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SALVAGE THERAPY; TREATMENT DURATION;

EID: 84907856833     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2014.5516     Document Type: Article

References (18)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-623.
2. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969-78.
3. Kell WJ, Burnett A., Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-83.
4. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59.
5. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715-27.
6. Ivanoff S, Gruson B, Chantepie S P, et al. Azacitidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol 2013;88:601-5.
7. Al-Ali HK, Jaekel N, Niederwieser D. The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol 2014;5:85-109.
8. Estey EH. Spotlight on epigenetics in hematological malignancies. Epigenentics in clinical practice: the example of azacyti-dine and decitabine. Leukemia 2013; 27:1803-12.
9. Von Hoff DD, Slavik M, Muggia FM, et al. 5-Azacytidine: a new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 1976;85:237-45.
10. Tawfik B, Silesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute leukemia. Ann Hematol 2014;93:47-55.
11. Itzykson R, Thépot S, Recher S, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program. Blood 2009;114:1054.
12. Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res 2008;32:1221-27.
13. Silverman L, Verma A, Odchimar-Reissig R, et al. A phase II trial of epigenetic modulators vorinostat with azacitidine in patients with the myelodysplastic syndrome: initial results of study 6898 of the New York cancer consortium. Blood 2013;122:21.
14. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121:4655-62.
15. Ghanem H, Tank N, Tabbara I, et al. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics. Am J Hematol 2012; 87:69-77.
16. Walker A, Marcucci G. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Exp Rev Hematol 2012;5:547-58.
17. Costa C, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011;117:2690-96.
18. Bellomo J, Parlier V, Muhlematter D et al. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992; 59:138-60.